Share this page
SCN 2018-19 Funding Results: Clinical Trials
| Principal Investigator | Co-Investigator | Project Title | SCN Funds Allocated |
|---|---|---|---|
| Jean Roy – Hôpital Maisonneuve- Rosemont (HMR) | Guy Sauvageau (UdeM), Jean-Sebastien Delisle (HMR), Richard Leblanc (HMR), Sandra Cohen (HMR), Silvy Lachance (HMR), Imran Ahmad (HMR), Émilie Lemieux-Blanchard (CRCHUM), Michael Sebag (MUHC), Sebastien Lemieux (UdeM), Gabriel Tremblay (Geneconomic) | Allogeneic stem cell transplant using UM171 expanded cord bloods for patients with high-risk multiple myeloma | $500,000 |
| James Shapiro – U of A | Peter Senior (U of A), Peter Light (U of A), Gregory Korbutt (U of A), Eugene Brandon (Viacyte Inc.), Kevin D’Amour (Viacyte Inc.), Howard Foyt (Viacyte Inc.), Sylvain Bedard (CEPPP), Bart Roep (U Leiden), Joanna Preston (TEC Edmonton), Chris McCabe (U of A) | Pancreatic Progenitor Cell Therapy: Solving Supply and Survival Issues of Islet Cell Transplantation for T1DM | $500,000 |
| Duncan Stewart – OHRI | David Courtman (GMP Facility OHRI), Michael Kutryk (SMH), Chris Glover (UOHI), Hung-Ly Quoc (MHI), Alexander Dick (UOHI), Michel Lemay (UOHI), Kim Connelly (SMH), Howard Leong Poi (SMH), Josep Rodes-Cabau (U Laval), Dominique Joyal (JGH) | Enhanced Angiogenic Cell Therapy for Acute Myocardial Infarction (ENACT-AMI) | $500,000 |
Clinical Trials Summary
| Applications Received | Applications Recommended for Funding | Percentage of Successful Applications | Total Investment |
|---|---|---|---|
| 4 | 3 | 75% | $1.5 million |
SCN 2018-19 Funding Results: Disease Team Program
| Principal Investigator | Co-Investigator | Project Title | SCN Funds Allocated |
|---|---|---|---|
| Gilbert Bernier – Hôpital Maisonneuve- Rosemont (HMR) | May Griffith (UdeM), Jean-Francois Bouchard (UdeM), Flavio Rezende (HMR), Cynthia Qian (UdeM), Mario Filion (INRS) | Macula transplantation for the treatment of retinal degenerative diseases | $200,000 |
| Joanna Matsubara – UBC | Marinko Sarunic (SFU), David Maberly (UBC), Orson Moritz (UBC), Arif Samad (DU), Sean Lumb (UBC) | Treating advanced retinal degeneration – rebuilding multiple co-dependent retinal layers with stem cells | $100,000 |
| Lauralyn McIntyre – OHRI | Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (Hamilton Health Sciences Corporation), Margaret Herridge (UHN), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI), Dana Devine (CBS) | Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial | $200,000 |
| Freda Miller – The Hospital for Sick Children (HSC) | Donald Mabbott (HSC), David Kaplan (HSC), Cindi Morshead (U of T), Jing Wang (OHRI), Ann Yeh (HSC), Douglas Munoz (Queens U), Paul Frankland (HSC), Wolfram Tetzlaff (UBC), Brian Nieman (HSC) | Pharmacological recruitment of endogenous neural precursors to promote pediatric white matter repair | $200,000 |
| Massimiliano Paganelli – CHU Sainte-Justine, UdeM | Elie Haddad (UdeM), Christian Beausejour (UdeM), Ariella Shikanov (U of Michigan), Serge McGraw (UdeM), Yves Théoret (CHU Sainte-Justine), Michel Lallier (CHU Sainte-Justine) | Safety and efficacy of stem cell-derived encapsulated liver tissue to treat liver failure without immunosuppression | $100,000 |
| James Shapiro – U of A | Gregory Korbutt (U of A), ViaCyte Inc., Joanna Preston (TEC Edmonton), Peter Senior (U of A), Bruce Verchere (UBC) | Development of a novel stem cell-derived transplant modality for type 1 diabetes | $100,000 |
| Bruce Verchere – UBC | Francis Lynn (UBC), Megan Levings (UBC), Tim Kieffer (UBC), Dina Panagiotopoulos (UBC), Brad Hoffman (UBC), Garth Warnock (UBC), Gregory Korbutt (UofA) | Genetic manipulation of hES-derived insulin-producing cells to improve graft outcomes | $200,000 |
Disease Team Program Summary
| Applications Received | Applications Recommended for Funding | Percentage of Successful Applications | Total Investment |
|---|---|---|---|
| 11 | 7 | 64% | $1.1 million |
SCN 2018-19 Funding Results: Impact Research Program
| Investigators | Project Stream | Project Title | SCN Funds Allocated |
|---|---|---|---|
| Florian Bentzinger – UdeSherbrooke (Principal Investigator) Eric Marsault (UdeSherbrooke), Mannix Auger-Messier (UdeSherbrooke), Nicolas Dumont (CHU-Sainte-Justine, UdeM), Frederic Balg (UdeSherbrooke) | Discovery Translation | Apelinergic Compounds for the treatment of muscular dystrophy | $99,000 |
| Mick Bhatia – McMaster (Principal Investigator) Rima Al-Awar (OICR) | Discovery Translation | Identification of kinases and their target substrates in early human PSC specification | $100,000 |
| Timothy Caulfield – U of A (Principal Investigator) Amy Zarzeczny (UofR), Barbara von Tigerstrom (UofA), Tania Bubela (SFU), Yann Joly (McGill), Zubin Master (Mayo Clinic), Jeremy Snyder (SFU), Ubaka Ogbogu (UofA) | Public Policy | The Next Step: Specific Strategies for Addressing the Marketing of Unproven Stem Cell Therapies | $40,000 |
| Nicolas Dumont – CHU Sainte-Justine, UdeM (Principal Investigator) Sylvie Girard (UdeM), Cam-Tu Nguyen (UdeM), Phillipe Campeau (UdeM), Christian Beauséjour (UdeM) | Discovery Translation | Targeting muscle stem cells to mitigate Duchenne muscular dystrophy | $100,000 |
| John Hassell – McMaster (Principal Investigator) Rima Al-awar (OICR) | Discovery Translation | HTR5A as a target for anticancer stem cell drug discovery | $99,500 |
| Timothy Kieffer – UBC (Principal Investigator) Ali Rezania (Viacyte Inc.) | Clinical Translation & Accelerator | Assessment of Cell Maturation and Function in Subcutaneous Macroencapsulation Devices in Rodents | $100,000 |
| Bartha Knoppers – McGill (Principal Investigator) Rosario Isai (OHRI), Tim Caulfield (UofA), Amy Zarzeczny (UofR), Tania Bubela (SFU), Ubaka Ogbogu (UofA), Vardit Ravitsky (UdeM) | Public Policy | Reforming Canadian Stem Cell Policy: Moving Beyond the Assisted Human Reproduction Act (AHRA) | $39,736 |
| Zachary Laksman – UBC (Principal Investigator) Glen Tibbits (SFU) | Clinical Translation & Accelerator | Using stem cells to test new drugs for atrial fibrillation | $100,000 |
| Lauralyn McIntyre – OHRI (Principal Investigator) Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (McMaster), Margaret Herridge (U of T), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI) | Clinical Translation & Accelerator | Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial | $100,000 |
| Derrick Rancourt – UC (Principal Investigator) Eric Jervis (STEMCELL Technologies) | Commercialization | Enhancing the Efficiency of Genome Engineering in Human Pluripotent Stem Cells | $100,000 |
| Bernard Thébaud – OHRI (Principal Investigator) Mervin Yoder (Hospital for Children, Indianapolis), Dylan Burger (U of O) | Clinical Translation & Accelerator | Endothelial Progenitor Cell-derived Therapies for Neonatal Pulmonary Hypertension | $99,905 |
| Glen Tibbits – SFU (Principal Investigator) Thomas Claydon (SFU), Zachary Laksman (UBC), Shubhayan Sanatani (UBC) | Clinical Translation & Accelerator | Developing an hiPSC-CM based protocol to investigate SIDS-implicated sudden cardiac arrest in infants | $99,500 |
| Eve Tsai – OHRI (Principal Investigator) Xudong Cao (U of O), Ruth Slack (U of O) | Clinical Translation & Accelerator | Translating an animal endogenous stem/progenitor cell repair strategy for stroke to humans | $100,000 |
| Peter Zandstra – UBC (Principal Investigator) Fiona Watt (King’s College, London, UK), Davide Danovi (King’s College, London, UK) | Commercialization | A robust, quantitative, and high-throughput assay to rapidly characterize human induced pluripotent stem cells | $100,000 |
Impact Research Program Summary
| Applications Received | Applications Recommended for Funding | Percentage of Successful Applications | Total Investment |
|---|---|---|---|
| 46 | 14 | 30% | $1.4 million |
* Project titles posted as per the language of submission